OVID
Ovid Therapeutics Inc (OVID)
Healthcare • NASDAQ • $2.74-6.48%
- Symbol
- OVID
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $2.74
- Daily Change
- -6.48%
- Market Cap
- $528.19M
- Trailing P/E
- N/A
- Forward P/E
- -7.18
- 52W High
- $3.11
- 52W Low
- $0.84
- Analyst Target
- $5.69
- Dividend Yield
- N/A
- Beta
- N/A
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 201…
Company websiteResearch OVID on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.